Belluscura is an LSE AIM listed UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Their innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
TMT Acquisition is an LSE Main Market listed UK company that is engaged in the investment business. The principal activity of the Company is identifying and acquiring investment projects. The Company was formed to pursue opportunities to acquire businesses in the technology, media, and telecom sectors (TMT sectors).
On 3rd October 2023, the Boards of Belluscura and TMT Acquisition announced the terms of a recommended all share offer to be made by Belluscura for the whole of the issued and to be issued share capital of TMT Acquisition.
On 19th January 2024, the boards of Belluscura and TMT Acquisition, having regard to the Belluscura share price announced that they had agreed an increase in the number of new Belluscura Shares to be offered in exchange for TMT Acquisition Shares.
Publication of Offer Document and Rule 9 Waiver Circular
Having helped Belluscura when they floated on AIM in May 2021 and subsequently with the production of their Annual Reports, the Perivan shareholder communications team was delighted to work with Dowgate Capital who acted as Financial Advisor and Broker to Belluscura on the offer document, rule 9 waiver circular and associated ancillary documents at this next stage of their corporate journey, which were successfully published and posted to qualifying shareholders on 19th January 2024.
Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies and are a market leader for the production of documentation relating to Mergers & Acquisitions.